Efficacy and Safety of SPARC0921 in Subjects With Spasticity
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 30 May 2017
At a glance
- Drugs Baclofen (Primary)
- Indications Multiple sclerosis; Muscle spasticity
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Sun Pharma Advanced Research Company
- 24 May 2017 Planned End Date changed from 1 Jan 2018 to 1 Aug 2017.
- 24 May 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Aug 2017.
- 24 May 2017 Status changed from recruiting to active, no longer recruiting.